Guo Xin, Wu Min, Deng Yanping, Liu Yan, Liu Yanpeng, Xu Jianhua
The School of Pharmacy, Fujian Medical University, Fuzhou 350122, China.
Fujian Provincial Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University, Fuzhou 350122, China.
Pharmaceutics. 2023 May 19;15(5):1546. doi: 10.3390/pharmaceutics15051546.
The poor bioavailability of curcumin and its derivatives limits their antitumor efficacy and clinical translation. Although curcumin derivative C210 has more potent antitumor activity than curcumin, it has a similar deficiency to curcumin. In order to improve its bioavailability and accordingly enhance its antitumor activity in vivo, we developed a redox-responsive lipidic prodrug nano-delivery system of C210. Briefly, we synthesized three conjugates of C210 and oleyl alcohol (OA) via different linkages containing single sulfur/disulfide/carbon bonds and prepared their nanoparticles using a nanoprecipitation method. The prodrugs required only a very small amount of DSPE-PEG2000 as a stabilizer to self-assemble in aqueous solution to form nanoparticles (NPs) with a high drug loading capacity (~50%). Among them, the prodrug (single sulfur bond) nanoparticles (C210-S-OA NPs) were the most sensitive to the intracellular redox level of cancer cells; therefore, they could rapidly release C210 in cancer cells and thus had the strongest cytotoxicity to cancer cells. Furthermore, C210-S-OA NPs exerted a dramatic improvement in its pharmacokinetic behavior; that is, the area under the curve (AUC), mean retention time and accumulation in tumor tissue were 10, 7 and 3 folds that of free C210, respectively. Thus, C210-S-OA NPs exhibited the strongest antitumor activity in vivo than C210 or other prodrug NPs in mouse models of breast cancer and liver cancer. The results demonstrated that the novel prodrug self-assembled redox-responsive nano-delivery platform was able to improve the bioavailability and antitumor activity of curcumin derivative C210, which provides a basis for further clinical applications of curcumin and its derivatives.
姜黄素及其衍生物较差的生物利用度限制了它们的抗肿瘤功效及临床转化。尽管姜黄素衍生物C210比姜黄素具有更强的抗肿瘤活性,但其存在与姜黄素类似的缺陷。为了提高其生物利用度并相应增强其体内抗肿瘤活性,我们开发了一种C210的氧化还原响应脂质前药纳米递送系统。简而言之,我们通过包含单硫键/二硫键/碳碳键的不同连接方式合成了三种C210与油醇(OA)的缀合物,并采用纳米沉淀法制备了它们的纳米颗粒。这些前药仅需极少量的DSPE-PEG2000作为稳定剂,就能在水溶液中自组装形成具有高载药量(约50%)的纳米颗粒(NPs)。其中,前药(单硫键)纳米颗粒(C210-S-OA NPs)对癌细胞的细胞内氧化还原水平最为敏感;因此,它们能够在癌细胞中快速释放C210,从而对癌细胞具有最强的细胞毒性。此外,C210-S-OA NPs的药代动力学行为有显著改善;即曲线下面积(AUC)、平均滞留时间和在肿瘤组织中的蓄积量分别是游离C210的10倍、7倍和3倍。因此,在乳腺癌和肝癌小鼠模型中,C210-S-OA NPs在体内表现出比C210或其他前药纳米颗粒更强的抗肿瘤活性。结果表明,这种新型前药自组装氧化还原响应纳米递送平台能够提高姜黄素衍生物C210的生物利用度和抗肿瘤活性,为姜黄素及其衍生物的进一步临床应用提供了依据。